Skip to main content
. 2020 Dec 16;2020:8847306. doi: 10.1155/2020/8847306

Table 1.

Clinical and laboratory data of the 75 patients.

Values
Variants (N (%))
 MPA 38 (50.7%)
 GPA 21 (28.0%)
 EGPA 16 (21.3%)
Demographic data
 Age (years) 58.9 ± 15.1
 Male gender (N (%)) 26 (34.7%)
 Disease duration (months) 18.2 ± 32.2
AAV-specific indices
 BVAS 9.6 ± 6.8
 FFS (2009) 1.3 ± 0.9
 VDI 3.2 ± 1.7
 SF-36 PCS score 49.9 ± 23.3
 SF-36 MCS score 56.8 ± 21.5
Clinical manifestations (N (%))
 General 26 (34.7%)
 Cutaneous 9 (12.0%)
 Mucous membrane and eye 5 (6.7%)
 Ear, nose, and throat 35 (46.7%)
 Pulmonary 48 (64.0%)
 Cardiovascular 5 (6.7%)
 Abdominal 0 (0.0%)
 Renal 38 (50.7%)
 Nervous system 16 (21.3%)
ANCA positivity (N (%))
 P-ANCA 41 (54.7%)
 C-ANCA 7 (9.3%)
 MPO-ANCA 37 (49.3%)
 PR3-ANCA 6 (8.0%)
 ANCA positivity 49 (65.3%)
Laboratory data
 WBC count (/mm3) 8.9 ± 4.4
 Hemoglobin (g/dL) 11.6 ± 2.4
 Platelet count (×1000/mm3) 303.3 ± 141.6
 Blood urea nitrogen (mg/dL) 24.8 ± 16.7
 Creatinine (mg/dL) 1.7 ± 1.8
 Total protein (g/dL) 6.3 ± 0.7
 Serum albumin (g/dL) 3.6 ± 0.7
 AST (IU/L) 20.9 ± 12.8
 ALT (IU/L) 24.4 ± 20.9
 ESR (mm/hr) 44.6 ± 33.3
 CRP (mg/L) 19.4 ± 39.8
SAA (ng/mL) 876.0 ± 825.0

Values are expressed as mean ± standard deviation or number (percentage). MPA: microscopic polyangiitis; GPA: granulomatosis with polyangiitis; EGPA: eosinophilic granulomatosis with polyangiitis; AAV: ANCA-associated vasculitis; ANCA: antineutrophil cytoplasmic antibody; BVAS: Birmingham Vasculitis Activity Score; FFS: five-factor score; VDI: vasculitis damage index; SF-36: Short-Form 36-Item Health Survey; PCS: physical component summary; MCS: mental component summary; P: perinuclear; C: cytoplasmic; MPO: myeloperoxidase; PR3: proteinase 3; WBC: white blood cell; AST: aspartate aminotransferase; ALT: alanine aminotransferase; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; SAA: serum amyloid A.